Assessment of early response to tyrosine kinase inhibitor (erlotinib) in stage IIIB/IV NSCLC by PET/CT

被引：0
|
作者：
Benz, Matthias [1 ]
Walter, Franziska [2 ]
Garon, Edward [3 ]
Phelps, Michael [2 ]
Czernin, Johannes [2 ]
Allen-Auerbach, Martin [1 ]
机构：
[1] Univ Freiburg, Nucl Med, Freiburg, Germany
[2] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Med, Los Angeles, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2011年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
426
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Stage IIIb or IV NSCLC lung cancer on CT, what is the point of a F-18 FDG PET/CT?
    Birchall, J. D.
    McCulloch, G.
    Mhlanga, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S293 - S293
  • [2] STAGE IIIB OR IV NSCLC LUNG CANCER ON CT, WHAT IS THE POINT OF F-18 FDG PET/CT?
    Birchall, J.
    Kumar, M.
    McCulloch, G.
    RADIOTHERAPY AND ONCOLOGY, 2010, 94 : S32 - S32
  • [3] DOES SERINE/THREONINE KINASE ACTIVITY COMPLEMENT THE TYROSINE KINASE ACTIVITY BASED RESPONSE PREDICTION TO NEOADJUVANT ERLOTINIB TREATMENT IN EARLY STAGE NSCLC?
    Hilhorst, M. H.
    Schaake, E. E.
    van Pel, R.
    Nederlof, P. M.
    Houkes, L.
    Mommersteeg, M.
    de Wijn, R.
    Ruijtenbeek, R.
    van den Heuvel, M. M.
    Baas, P.
    Klomp, H. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 39 - 39
  • [4] Tarceva - Erlotinib - Genentech/Osi pharmaceuticals - Tyrosine kinase inhibitor approved for NSCLC
    不详
    FORMULARY, 2004, 39 (12) : 568 - 568
  • [5] Is FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with NSCLC?
    Aukema, T. S.
    Kappers, I.
    Olmos, R. A. Valdes
    Codrington, H. E.
    Van Tinteren, H.
    Van Pel, R.
    Klomp, H. M.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 : S128 - S129
  • [6] PET imaging of early response to the tyrosine kinase inhibitor ZD4190
    Min Yang
    Haokao Gao
    Yongjun Yan
    Xilin Sun
    Kai Chen
    Qimeng Quan
    Lixin Lang
    Dale Kiesewetter
    Gang Niu
    Xiaoyuan Chen
    European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38 : 1237 - 1247
  • [7] PET imaging of early response to the tyrosine kinase inhibitor ZD4190
    Yang, Min
    Gao, Haokao
    Yan, Yongjun
    Sun, Xilin
    Chen, Kai
    Quan, Qimeng
    Lang, Lixin
    Kiesewetter, Dale
    Niu, Gang
    Chen, Xiaoyuan
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (07) : 1237 - 1247
  • [8] Impact of EMT in stage IIIB/IV NSCLC treated with erlotinib and bevacizumab when compared with cisplatin, gemcitabine and bevacizumab
    Villalobos, Matthias
    Czapiewski, Piotr
    Reinmuth, Niels
    Fischer, Juergen R.
    Andreas, Stefan
    Kortsik, Cornelius
    Serke, Monika
    Wolf, Martin
    Neuser, Petra
    Reuss, Alexander
    Schnabel, Philipp A.
    Thomas, Michael
    ONCOLOGY LETTERS, 2019, 17 (06) : 4891 - 4900
  • [9] Response evaluation after immunotherapy in NSCLC Early response assessment using FDG PET/CT
    Park, Sohyun
    Lee, Youngjoo
    Kim, Tae-Sung
    Kim, Seok-ki
    Han, Ji-Youn
    MEDICINE, 2020, 99 (51) : E23815
  • [10] MET-Lung: A Phase III Trial of Onartuzumab (METMab) Plus Erlotinib vs Erlotinib in Previously Treated Stage IIIB or IV NSCLC
    Kelly, K.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1709 - S1710
12345